Form 4: Nuo Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
David Emerson Jorden, CEO/CFO and a Director of Nuo Therapeutics, Inc., reported multiple transactions in common stock on August 27, 2026.
Summary
- Grant/award: acquired 789 Common Stock at $1.07 ($844) on August 27, 2026; holds 2,062,016 after (Direct).
- Grant/award: acquired 7,984 Common Stock at $1.09 ($8,695) on August 28, 2026; holds 2,070,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Emerson Jorden — Director, Officer (CEO/CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-27 | Grant/award | Common Stock | 789 | $1 | $844 | 2,062,016 |
| 2026-08-28 | Grant/award | Common Stock | 7,984 | $1 | $8.7K | 2,070,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-27 | Grant/award (789 shares) |
| 2026-08-28 | Grant/award (7,984 shares) |
Keywords
insider transaction, Form 4, AURX, Nuo Therapeutics, Inc., neutral, David Emerson Jorden
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.